MyLeukemiaTeam

How is Jakafi used to treat chronic neutrophilic leukemia?

Jakafi (ruxolitinib) may be used as a treatment option for chronic neutrophilic leukemia (CNL) when chemotherapy doesn't effectively control the disease. It's a kinase inhibitor that works by blocking enzymes responsible for making cancer cells grow out of control.

How is Jakafi used to treat chronic neutrophilic leukemia?

Jakafi (ruxolitinib) may be used as a treatment option for chronic neutrophilic leukemia (CNL) when chemotherapy doesn't effectively control the disease. It's a kinase inhibitor that works by blocking enzymes responsible for making cancer cells grow out of control.

While Jakafi isn't officially FDA-approved specifically for CNL, it has helped some people with this condition achieve positive outcomes. It's currently being studied as a CNL treatment in clinical trials.

Jakafi is FDA-approved for other types of myeloproliferative neoplasms (MPNs), which are in the same family of blood cancers as CNL.

Keep in mind that CNL is extremely rare, with only about 200 cases ever documented, so treatment options are still being researched and refined.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Chronic Neutrophilic Leukemia: An Overview